Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.
暂无分享,去创建一个
W. Keitel | R. Belshe | J. Treanor | R. Edelman | Wilbur H. Chen | D. Noah | R. Atmar | P. Winokur | R. Brady | H. Hill | Irene L Graham | K. Guo | Kuo Guo
[1] Y. Guan,et al. Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.
[2] W. Keitel,et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. , 2008, The Journal of infectious diseases.
[3] D. Bernstein,et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. , 2008, The Journal of infectious diseases.
[4] J. Treanor,et al. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. , 2008, The Journal of infectious diseases.
[5] R. Couch,et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] J. Treanor,et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. , 2008, The Journal of infectious diseases.
[7] M. Zambon,et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.
[8] Mark Wolff,et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.
[9] E. Neumeier,et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. , 2004, Virus research.
[10] Giuseppe Del Giudice,et al. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile , 2003, Expert review of vaccines.
[11] E. Neumeier,et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines , 2002, Medical Microbiology and Immunology.
[12] W. Beyer,et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. , 1989, Vaccine.